Ark Therapeutics Group plc today announces that the US
Patent Office has granted the Company a patent covering the use of Vitor(TM) in
muscle wasting (cachexia) conditions (US 7071183). Vitor(TM) is an oral small
molecule therapy currently in Phase III development for the treatment of
patients with cancer cachexia, which, together with the associated weakness, is
one of the most distressing aspects of late stage cancer. The grant gives
protection until 2018. The patent for Europe was granted in 2005.
